Labiotech.eu

News and Trends 15 Jul 2016

Compugen is Hunting down ‘Hot’ zone Targets for Immuno-Oncology

Israel, we’re on our way! We leave Denmark with a smile and head down to sunny Tel-Aviv, where Compugen, a big Israeli-based leading drug discovery company and our Biotech of The Week, is located. City: Tel-Aviv (Israel) Founded: 1993 Employees: 93 (as of 03/2016) Financial Data: €257.2M Market Cap (on 22/03/2016) CEO: Anat Cohen-Dayan Mission: Compugen-discovered drug targets are primarily […]

July 15, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 14 Jul 2016

Institut Pasteur & Austrian Biotech also join the World Zika Vaccine Plan

Themis is a Vienna-based vaccine developer. Together with the Institut Pasteur, it is now planning to use a measles vaccine construct to develop and start Zika vaccine trials within the next 12 months. Themis has successfully extended its existing license agreement with Institut Pasteur in Paris, which grants the company a broad access to a well-established virus vaccine vector technology. The […]

July 14, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 14 Jul 2016

Sci-fi Spinal Cord Implant could help Paralyzed Patients walk again

Getting up from a wheelchair is a shared dream of paralyzed people all across the world. A dream that might soon become true thanks to a new skin-like implant that directly stimulates the patients’ spinal cord through electric pulses. The sci-fi technology developed by researchers at École Polytechnique Fédérale of Lausanne (EPFL) in Switzerland has […]

July 14, 2016 - 2 minutesmins - By Lourdes Riquelme

oxitec brazil mosquito gmo vector control zika dengue malaria city

News and Trends 14 Jul 2016

UPDATE: Brazilian city to be first in World to deploy GM Mosquitos against Dengue Fever

Oxitec‘s genetically engineered Mosquito trial is being expanded in Brazil’s Piracicaba region, to cover a city of over 60,000 people. With support from Ministry officials and the WHO, this UK biotech is making serious progress with their transgenic organism solution for Infectious diseases. UPDATE: (Article originally published 3/06/16). Just announced (14/07/16): The results from the trial […]

July 14, 2016 - 4 minutesmins - By Dani Bancroft

pharnext marie tooth disease IPO pharnext

News and Trends 14 Jul 2016

French Biotech that makes Drugs faster and cheaper IPO’s for €31M

Pharnext has successfully completed its IPO on the Euronext Paris exchange, allowing it to move forward with Phase II and III trials for Neurological diseases that include Alzheimer’s. Based in Paris, Pharnext is developing new therapies for neurological conditions, including rare diseases such as Charcot-Marie-Tooth Disease. New partners to join this biotech in the €31M IPO include Galapagos […]

July 14, 2016 - 2 minutesmins - By Dani Bancroft

servier sorrento pd 1 biotech chemo car t cancer

News and Trends 13 Jul 2016

French Pharma licenses California PD-1 Cancer Antibody for €710M

San Diego’s Sorrento Therapeutics has bagged a quarter-billion euro deal with Servier. The French Pharma giant will develop Sorrento’s PD-1 targeting platform – a key checkpoint inhibitor in Immuno-Oncology. Sorrento’s proprietary G-MAB library platform was used to identify and generate STI-A1110, an antibody which targets PD-1, one of the key targets in the rapidly developing immuno-oncology therapy […]

July 13, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 13 Jul 2016

Europe’s most valuable Biotech just launched 2 new Trials

Within a week, Actelion has announced both Phase II and III trial studies for insomnia and hypertension in children. Even for Europe’s most valuable biotech, this is an impressive period. Actelion is to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia. The day before this, it also announced a […]

July 13, 2016 - 3 minutesmins - By Dani Bancroft

ono pharmaceutical biotech celyad cancer nk cell therapy

News and Trends 12 Jul 2016

Unique Natural Killer T-Cell Therapy secures €282M in Japan Deal

Belgian Celyad granted an exclusive license to Osaka based ONO Pharmaceutical for the development and commercialisation of Celyad’s unique allogeneic cell therapy in Japan, Korea and Taiwan. This license agreement opens new markets to Celyad and its NKR-2 T-cell cancer immunotherapy. In addition to a deal worth up to €282M, Celyad will also receive double digit royalties based on […]

July 12, 2016 - 3 minutesmins - By Dani Bancroft

HIV diagnostic helen lee epo biotech inventor europe samba

News and Trends 12 Jul 2016

How did Helen Lee overcome barriers to HIV Diagnostics in the ‘Real World’?

How can diagnostics be improved in resource limited settings? And how can the practical limitations of transporting heat-sensitive assay material through hot climates be overcome? The University of Cambridge’s Dr Helen Lee won this year’s ‘Popular Choice’ Award, at the European Patent Office (EPO) awards. The winner of this prize category is selected from 15 other […]

July 12, 2016 - 6 minutesmins - By Dani Bancroft

News and Trends 12 Jul 2016

Which European Biotechs made it to the Billion-Euro Club in 2016?

Europe has a lot of successful Biotech companies, but which of those are worth a billion euros or more? I did a previous version of this article last year and now I explore how these have evolved. Just 9 European Biotech companies (private and public) are worth over one billion right now. Many of these were present last year. For […]

July 12, 2016 - 6 minutesmins - By Philip Hemme

News and Trends 11 Jul 2016

On the way to a ‘Functional’ HIV Cure? Norway Vaccine clears viral load in 88% of Patients

Oslo based Biopharma Bionor has a Phase I results for a HIV vaccine. The vaccine infusion rendered viral presence in 88% of patients undetectable after combination treatments with Celgene‘s enzyme inhibitor, Istodax and standard retroviral drugs. The positive results from the clinical trial REDUC Part B were published in the high impact journal The Lancet HIV. The Norwegian’s proprietary […]

July 11, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 11 Jul 2016

After Genentech, Roche could acquire another American Billion-dollar Biotech

Roche is rumored to make a move on the California biotech BioMarin. Despite a slightly weakened pipeline, Roche appears undeterred and previous offers were predicted to be around $15Bn. As big as some of the other industry veterans, BioMarin was founded in the 90’s boom in Biotech in San Rafaele, California. The deal itself is entirely based on […]

July 11, 2016 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Compugen is Hunting down ‘Hot’ zone Targets for Immuno-Oncology

Institut Pasteur & Austrian Biotech also join the World Zika Vaccine Plan

Sci-fi Spinal Cord Implant could help Paralyzed Patients walk again

UPDATE: Brazilian city to be first in World to deploy GM Mosquitos against Dengue Fever

French Biotech that makes Drugs faster and cheaper IPO’s for €31M

French Pharma licenses California PD-1 Cancer Antibody for €710M

Europe’s most valuable Biotech just launched 2 new Trials

Unique Natural Killer T-Cell Therapy secures €282M in Japan Deal

How did Helen Lee overcome barriers to HIV Diagnostics in the ‘Real World’?

Which European Biotechs made it to the Billion-Euro Club in 2016?

On the way to a ‘Functional’ HIV Cure? Norway Vaccine clears viral load in 88% of Patients

After Genentech, Roche could acquire another American Billion-dollar Biotech

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!